Head to Head Analysis: Moolec Science (MLEC) vs. Its Peers

Moolec Science (NASDAQ:MLEC) is one of 495 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Moolec Science to related companies based on the strength of its analyst recommendations, profitability, risk, institutional ownership, valuation, earnings and dividends.

Valuation and Earnings

This table compares Moolec Science and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.34
Moolec Science Competitors	$211.82 million	-$15.63 million	116.80

Moolec Science’s competitors have higher revenue, but lower earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 33.5% of shares of all “Biotechnology” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by company insiders. Comparatively, 19.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Moolec Science has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s competitors have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.

Profitability

This table compares Moolec Science and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-7,267.69%	-105.83%	-28.54%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Moolec Science and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	963	2818	7056	105	2.58

Moolec Science currently has a consensus price target of $6.00, suggesting a potential upside of 590.61%. As a group, “Biotechnology” companies have a potential upside of 23.86%. Given Moolec Science’s stronger consensus rating and higher possible upside, research analysts clearly believe Moolec Science is more favorable than its competitors.

Summary

Moolec Science beats its competitors on 7 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.